Christopher J Langmead

List of Publications by Citations

80 papers	3,849 citations	31 h-index	61 g-index
91 ext. papers	4,308 ext. citations	7.6 avg, IF	5.23 L-index

#	Paper	IF	Citations
80	Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. *Nature*, **2011**, 474, 521-5	50.4	685
79	Muscarinic acetylcholine receptors as CNS drug targets **2008**, 117, 232-43		320
78	Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. *Journal of Medicinal Chemistry*, **2012**, 55, 1898-903	8.3	263
77	Progress in structure based drug design for G protein-coupled receptors. *Journal of Medicinal Chemistry*, **2011**, 54, 4283-311	8.3	191
76	International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. *Pharmacological Reviews*, **2014**, 66, 918-47	22.5	156
75	The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. *Neuropharmacology*, **2011**, 60, 36-44	5.5	133
74	Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. *British Journal of Pharmacology*, **2004**, 141, 340-6	8.6	114
73	Identification of novel adenosine A(2A) receptor antagonists by virtual screening. *Journal of Medicinal Chemistry*, **2012**, 55, 1904-9	8.3	110
72	Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. *British Journal of Pharmacology*, **2008**, 154, 1104-15	8.6	108
71	Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. *Trends in Pharmacological Sciences*, **2006**, 27, 475-81	13.2	106
70	Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. *Molecular Pharmacology*, **2007**, 72, 463-76	4.3	98
69	Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. *Molecular Pharmacology*, **2006**, 69, 236-46	4.3	94
68	Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. *European Journal of Pharmacology*, **2005**, 510, 49-57	5.3	93
67	Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. *Molecular Pharmacology*, **2010**, 78, 94-104	4.3	57
66	Neurochemical changes in LPA1 receptor deficient mice--a putative model of schizophrenia. *Neurochemical Research*, **2005**, 30, 371-7	4.6	56
65	Pharmacology and structure of isolated conformations of the adenosine A2A receptor define ligand efficacy. *Molecular Pharmacology*, **2013**, 83, 949-58	4.3	53
64	G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. *Pharmacological Reviews*, **2018**, 70, 39-67	22.5	53

63	Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. *Neuroscience Letters*, **2004**, 366, 241-4	3.3	51
62	Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. *British Journal of Pharmacology*, **2014**, 171, 351-63	8.6	50
61	G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 327, 365-74	4.7	50
60	Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. *Molecular Pharmacology*, **2009**, 75, 331-41	4.3	47
59	Characterization of the binding of [(125)I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor. *British Journal of Pharmacology*, **2000**, 131, 683-8	8.6	46
58	Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists. *ACS Medicinal Chemistry Letters*, **2010**, 1, 244-8	4.3	45
57	Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. *Molecular Pharmacology*, **2011**, 79, 874-85	4.3	41
56	Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. *Molecular Cell*, **2020**, 80, 485-500.e7	17.6	41
55	Evaluation of expression and function of the H+/myo-inositol transporter HMIT. *BMC Cell Biology*, **2009**, 10, 54		38
54	Roof and floor of the muscarinic binding pocket: variations in the binding modes of orthosteric ligands. *Molecular Pharmacology*, **2007**, 72, 1484-96	4.3	38
53	New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery. *ACS Pharmacology and Translational Science*, **2020**, 3, 88-106	5.9	36
52	The effect of SB-269970, a 5-HT(7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. *British Journal of Pharmacology*, **2001**, 132, 1574-80	8.6	35
51	Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants. *PLoS ONE*, **2016**, 11, e0146846	3.7	35
50	The use of GPCR structures in drug design. *Advances in Pharmacology*, **2011**, 62, 1-36	5.7	34
49	Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 331, 1086-95	4.7	31
48	Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor. *Molecular Pharmacology*, **2009**, 76, 802-11	4.3	31
47	Functional and structural perspectives on allosteric modulation of GPCRs. *Current Opinion in Cell Biology*, **2014**, 27, 94-101	9	29
46	Crystal structure of the M muscarinic acetylcholine receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 26001-26007	11.5	27

45	Monoclonal anti-1-adrenergic receptor antibodies activate G protein signaling in the absence of arrestin recruitment. *MAbs*, **2014**, 6, 246-61	6.6	25
44	Matching models to data: a receptor pharmacologist's guide. *British Journal of Pharmacology*, **2010**, 161, 1276-90	8.6	24
43	Supra-physiological efficacy at GPCRs: superstition or super agonists?. *British Journal of Pharmacology*, **2013**, 169, 353-6	8.6	21
42	N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor. *Neuropharmacology*, **2010**, 58, 1206-14	5.5	21
41	Bitopic Binding Mode of an M Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. *Molecular Pharmacology*, **2018**, 93, 645-656	4.3	20
40	Muscarinic M receptors modulate ethanol seeking in rats. *Neuropsychopharmacology*, **2018**, 43, 1510-1518	7.7	19
39	Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity. *British Journal of Pharmacology*, **2018**, 175, 4095-4108	8.6	18
38	Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators. *Molecular Pharmacology*, **2016**, 90, 427-36	4.3	18
37	Structure-based development of a subtype-selective orexin 1 receptor antagonist. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 18059-18067	11.5	18
36	Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research. *PLoS ONE*, **2018**, 13, e0197177	3.7	18
35	Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H receptor antagonists. *Neuropharmacology*, **2019**, 144, 244-255	5.5	17
34	Isoform-Specific Biased Agonism of Histamine H3 Receptor Agonists. *Molecular Pharmacology*, **2017**, 91, 87-99	4.3	16
33	2Sbiaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3545-9	2.9	16
32	2Sbiaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3540-4	2.9	16
31	Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists. *Molecular Pharmacology*, **2015**, 88, 779-90	4.3	15
30	Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 359, 354-365	4.7	15
29	SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue. *European Journal of Pharmacology*, **2006**, 536, 54-61	5.3	13
28	Determining allosteric modulator mechanism of action: integration of radioligand binding and functional assay data. *Methods in Molecular Biology*, **2011**, 746, 195-209	1.4	13

27	Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. *MedChemComm*, **2015**, 6, 947-955	5	11
26	Acetylcholine Muscarinic M Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. *Biological Psychiatry*, **2020**, 88, 898-909	7.9	10
25	Negative allosteric modulators of the human calcium-sensing receptor bind to overlapping and distinct sites within the 7-transmembrane domain. *British Journal of Pharmacology*, **2020**, 177, 1917-1930	8.6	10
24	In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. *European Journal of Pharmacology*, **2010**, 627, 106-14	5.3	9
23	The muscarinic M(4) receptor is the functionally predominant subtype in rat and mouse striatum as demonstrated using [(35)S] GTPS binding. *European Journal of Pharmacology*, **2011**, 652, 1-6	5.3	8
22	From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. *Cell*, **2021**, 184, 5886-5901.e22	56.2	8
21	Discovery and Optimization of Potent and CNS Penetrant M-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. *ACS Chemical Neuroscience*, **2018**, 9, 1572-1581	5.7	7
20	Screening for positive allosteric modulators: assessment of modulator concentration-response curves as a screening paradigm. *Journal of Biomolecular Screening*, **2007**, 12, 668-76		7
19	High throughput, quantitative analysis of human osteoclast differentiation and activity. *Analytical Biochemistry*, **2017**, 519, 51-56	3.1	6
18	Ligand properties and behaviours in an allosteric age. *Trends in Pharmacological Sciences*, **2012**, 33, 621-2	13.2	6
17	Structure-Activity Relationships of Pan-G Coupled Muscarinic Acetylcholine Receptor Positive Allosteric Modulators. *ACS Chemical Neuroscience*, **2018**, 9, 1818-1828	5.7	5
16	SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2 methyl-4 (5-methyl-1,2,3-oxadiazol-3-yl)biphe hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist. *Neuropharmacology*, **2006**, 50, 984-90	5.5	5
15	Arrestin-2-Dependent Mechanism of GPR52 Signaling in Frontal Cortical Neurons. *ACS Chemical Neuroscience*, **2020**, 11, 2077-2084	5.7	4
14	Performance of mouse neural stem cells as a screening reagent: characterization of PAC1 activity in medium-throughput functional assays. *Journal of Biomolecular Screening*, **2010**, 15, 159-68		3
13	Muscarinic M and M receptors in the ventral subiculum differentially modulate alcohol seeking versus consumption in male alcohol-preferring rats. *British Journal of Pharmacology*, **2021**, 178, 3730-3746	8.6	3
12	Binding of SEP-363856 within TAAR1 and the 5HT receptor: implications for the design of novel antipsychotic drugs. *Molecular Psychiatry*, **2021**,	15.1	3
11	Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.. *Translational Psychiatry*, **2022**, 12, 147	8.6	3
10	In the Loop: Extrastriatal Regulation of Spiny Projection Neurons by GPR52. *ACS Chemical Neuroscience*, **2020**, 11, 2066-2076	5.7	2

9	Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms. *BMJ Open Diabetes Research and Care*, **2021**, 9,	4.5	2
8	Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. *ACS Pharmacology and Translational Science*, **2020**, 3, 1042-1062	5.9	2
7	M muscarinic receptor activation decreases alcohol consumption via a reduction in consummatory behavior.. *Pharmacology Research and Perspectives*, **2022**, 10, e00907	3.1	2
6	Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. *Frontiers in Pharmacology*, **2021**, 12, 628060	5.6	1
5	Identification of a Novel Allosteric Site at the M Muscarinic Acetylcholine Receptor. *ACS Chemical Neuroscience*, **2021**, 12, 3112-3123	5.7	1
4	Cryo-EM structure of the dual incretin receptor agonist, peptide-19, in complex with the glucagon-like peptide-1 receptor. *Biochemical and Biophysical Research Communications*, **2021**, 578, 84-90	3.4	1
3	Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities.. *ACS Pharmacology and Translational Science*, **2022**, 5, 183-188	5.9	1
2	Screening for Allosteric Modulators of G Protein-Coupled Receptors **2010**, 276-299		
1	GPR52 is a key regulator of corticostriatal signalling and function. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO3-1-100	0	